Immunome Reports Full Year 2024 Financial Results and Provides Business Update
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...
Zacks Investment Research on MSN10 天
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why
Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of ...
SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz
SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...
Morningstar3 天
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025. First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1 ...
Yahoo Finance13 天
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a ...
Yahoo Finance1 个月
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
The company generated revenues worth $5.4 million in the year-ago quarter. The FDA approved Ogsiveo for treating adult patients with progressing desmoid tumors who require systemic treatment in ...